U.S. Markets closed

Lupin Limited (LUPIN.NS)


NSE - NSE Real Time Price. Currency in INR
Add to watchlist
1,142.90-23.15 (-1.99%)
At close: 3:30PM IST
Full screen
Previous Close1,166.05
Open1,157.15
Bid1,142.90 x
Ask0.00 x
Day's Range1,131.25 - 1,157.15
52 Week Range1,036.20 - 1,750.00
Volume1,438,807
Avg. Volume1,733,366
Market Cap516.66B
BetaN/A
PE Ratio (TTM)20.24
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • What You Don't Know About Generic Drugs, and How It Can Hurt You
    Bloomberg26 days ago

    What You Don't Know About Generic Drugs, and How It Can Hurt You

    To keep his anxiety under control, Peter, a 35-year-old government employee, relied for nine years on a blue-and-white pill he popped every night before bed: Cymbalta, made by Eli Lilly & Co. When a generic ...

  • Reuters2 months ago

    Novartis CEO sees no need for big takeover

    Novartis does not need a big acquisition to kick-start growth, Chief Executive Joe Jimenez told investors on Wednesday, playing down suggestions he could use proceeds from a slew of asset sales for a significant takeover. Amid speculation Novartis might use proceeds to buy AstraZeneca or Bristol-Myers Squibb to fill holes in its cancer drug portfolio, Jimenez said he remained focused on smaller purchases of up to $5 billion to bolster his pipeline. "Obviously, there's been a lot of speculation because that would be a lot of capital," Jimenez said at an event at Novartis's research campus in Boston.

  • Reuters2 months ago

    Indian drugmaker Lupin warns of more pricing pressure as Q4 profit halves

    Indian drugmaker Lupin Ltd expects to launch over 30 products in the United States this year, but warned revenue growth would remain muted due to growing pricing pressure and competition in the world's largest healthcare market. "We've talked about medium single digits of price erosion in the past and I think we are now (seeing) high single digits," Managing Director Nilesh Gupta told Reuters after Lupin reported a quarterly profit that halved from a year earlier. The country's third-largest drugmaker has been working on building a pipeline of high-value complex generic drugs in the United States to offset growing competition in plain generics.